Gynecological applications of GNRH antagonists, a review
DOI:
https://doi.org/10.18597/rcog.746Keywords:
LHRH, GnRH, GnRH Antagonist, ovarian stimulation, cancer treatment, gonadotropins, uterine miomasAbstract
The modifications to the native LH-RH produced the appearance of the analogs: agonist whose applications in the area of reproductive medicine has been shown to be safe and effective in the treatment of different diseases, and antagonist of recent studies and appearance. There are special situations in which we need a fast suppression of endogenous gonadotropin production, and by the initial stimulatory effect of the analog, it is not accomplished. The use of the LH-RH antagonist cause an immediate inhibition of FSH and LH by competitive blockade of the receptors, which makes their use optimal in the case of assisted reproduction techniques and ovulation induction. Other potential indications would be those cases in which an endogenous suppression of the production of sex steroids is required, which is the case of benign prostatic hyperplasia, prostate carcinoma, ovarian carcinomas in which they have demonstrated a promissory utility.Author Biographies
José Ignacio Madero
Óscar Eduardo Guerra
Gabriel Barbosa
Carlos Morán
Pilar Gaitán
Mabel Ávila
Jesús Alberto Ruiz
References
Matsuo H, Baba Y, Nair R, et al. Structure of the porcine LH- and FSH-releasing hormone. Biochem Biophys Res Comm. 1971; 43: 1344-1339.
Burgus R, et al. Primary structure of the ovine hypothalamic luteinizing hormone releasing factor (LFR). Proc. Natl. Acad. Sci. USA. 1972; 69: 278.
Arimura A. The backstage story of the discovery of LHRH. Endocrinology 1991; 129: 1687-1689.
Shally A. Use of GnRH in preference to LH-RH terminology in scientific papers. Hum. Reprod. 2000; 15: 2059-2061.
Conn PM, Crowley WF. Jr. Gonadotrophin-releasing hormone and its analogues. N Engl J Med. 1991; 324: 93-103.
Loumaye E. The control of the endogenous secretion of luteinizing hormone by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Hum Reprod 1990; 5: 357-376.
Macnamee MC, Howles CM, Edwards RG. Short term luteinizing hormone-releasing hormone agonist treatment: prospective trial of a novel ovarian stimulation regimen for in vitro fertilization. Fertil Steril 1989; 52: 264-269.
Smitz J, Ron-El R, Tarlatzis BC. The use of gonadotrophin-releasing hormone agonist for in vitro fertilization and other assisted procreation techniques: experience from three centers. Hum Reprod 1992; 7(suppl 1): 49-66.
Loumaye E, Porchet HC, Beltrami V et al. Ovulation induction with recombinant human follicle-stimulating hormone and luteinizing hormone. En Filicori Marco y Flamigni Carlo (eds), Ovulation Induction. Basic Science and Clinical Advances. Elsevier Science, The Netherlands, pp. 227-236.
Edwards RG, Lobo R. and Bouchard P. Time to revolutionize ovarian stimulation. Hum Reprod. 1996; 11: 917-919.
Bajusz S, Kovacs M, Gazdag M, et al. Highly potent antagonist of LH-RH free of edematogenic effects. Proc. Natl Acad. Sci. USA, 1988; 85: 1637-1641.
The Ganirelix Dose-finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormones surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormones (Puregon). Hum Reprod 1998; 13: 3023-31.
Oberyé JJL, Mannaerts BMJL, Huisman JAM, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose- porportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril 1999; 72: 1006-1012.
Reissmann TH, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, and Schally AV. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 1995; 10: 1974-1981.
Reissmann T, Engel J, Kutscher B, et al. The LHRH antagonist Cetrorelix. Drugs Future 1994; 19: 228-237.
Pinski J, Yano T, Reissmann T, et al. Evaluation of the in vitro and in vivo activity of the L-,D,L- and D-Cit6 forms of the LHRH antagonist Cetrorelix(SB-75). Int. J. Peptide Protein Res. 1995; 45: 410-417.
Conn PM and Crowley WF. Gonadotropin releasing hormone and its analogs. N. Engl. J. Med. 1991; 324: 93-103.
Stojilkovic SS, Reinhart J. and Catt KJ. Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr. Rev. 1994; 15: 462-499.
Kaiser UB, Conn PM, and Chin WW. Studies of gonadotropin-releasing hormone(GnRH) action using GnRH receptor-expressing pituitary cells line. Endocr. Rev. 1997; 18: 46-70.
Horn F, Bilezikjian LM, Perrin MH, et al. Intracellular responses to gonadotropin-releasing hormone in a clonal cell line of gonadotrope lineage. Mol. Endocrinol. 1991; 5: 347.
Stojilkovic SS. and Katt KJ. Expression and signal transduction pathway of gonadotropin releasing hormone receptors. Recent. Prog. Horm. Res. 1995; 50:161-205.
Ortmann O, Ansari-Pirsarai B, Bloh P, et al. Modulatory actions of progesterone on gonadotropin releasing hormone induced arachidonic acid liberation from perifused rat pituitary cells. Eur. J. Endocrinol. 1996; 135: 626-630.
Ortmann O, Felberbaum R, Eick F, et al. The GnRH antagonist Cetrorelix does not affect steroidogenesis of human granulosa lutein cells. Exp. Clin. Endocrinol. (Suppl.), 1998.
Naor Z. Signal transduction mechanisms of calcium mobilizing hormones: the case of gonadotropin releasing hormone. Endocr. Rev., 1990; 11: 326-353.
Ortmann O, Tilse B. and Emons G. Modulatory actions of estradiol and progesterone on phorbol esther-estimulated LH secretion from cultured rat pituitary cells. J. Steroid Biochem. Mol. Biol. 1992; 43: 619-627.
Behre HM, Kliesch S, Puhse G, et al. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively supressmserum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men. J. Clin. Endocrinol. Metab. 1997; 82: 1403-1408.
Reissmann T, Schally AV, Bouchard P, Riethmuller H, Engel J. The LHRH antagonist Cetrorelix: a review. Hum Reprod Update 2000; 6: 322-331.
Duijkers IJM, Kippling C, et al. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotropin releasing hormone antagonist Cetrorelix in healthy female volunteers, Human Reproduction, 1998; 13: 2392-2398.
Oberyé JL, Mannaerts BMJL, Kleijn HJ, Timmer CJ. Pharmakinetic and pharmacodynamic characteristics of Ganirelix (Orgalutran). Part I. Absolut bioavailability of 0.25 mg of Ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil. Steril. 1999; 72: 1001-1005.
Schmutlzer RK, Diedrich K. Basic and Clinical aspects of GnRH-agonist in reproduction. Int. J. Gynecol. Obstet. 1990; 32: 311-324.
Olivennes F, Álvarez S, Bouchard P, et al. The use of a GnRH antagonist(Cetrorelix(r)) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mgr. Hum.Reprod. 1998; 13: 2411-2414.
Olivennes F, Fanchin R, Bouchard P, et al. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in vitro fertilization cycles: A pilot study. Hum Reprod. 1995; 10: 1382-1386.
Felberbaum R, Diedrich K. Ovarian stimulation for in vitro fertilization/intracitoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonist and antagonist. Hum. Reprod. 1999; 14: 207-221.
Sills ES, Levy DP, Moomjy M, et al. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization. Hum.Reprod. 1999; 14: 2230-2235.
Rongiéres-Bertrand C, Olivennes F, Righini C, et al. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin- releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum. Reprod. 1999; 14: 683-688.
Olivennes F, Belaisch-Allart J, Emperaire JC, et al. Prospective randomized controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000; 73: 314-320.
Felberbaum RE, Albano C, Ludig M, et al and on behalf of the European Cetrorelix Study Group. Hum Reprod. 2000; 15: 1015-1020.
The European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum.Rep. 2001; 16: 644-651.
Akman MA, Ereden HF, Tosun S, Bayazit N, Aksoy E, Bahceci M. Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Hum. Reprod. 2000; 15: 2145-2147.
Akman MA, Erden HF, Tosum SB, Bayasit N, Aksoy E, Bahceci M. Comparison of agonistic flare-up protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum. Reprod. 2001; 16: 868-870.
González-Barcena D, Banuelos Álvarez R, Pérez Ochoa E, et al. Treatment of uterine Leiomyomas with LHRH antagonist Cetrorelix. Hum. Reprod. 1997; 12: 2028-2035.
Felberbaum R, Germer U, Ludwid M, et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotropin releasing hormone antagonist Cetrorelix. Hum.Reprod. 1998; 13: 1660-1668.
Schally AV. LHRH Analogues: I. Their impact on the control of tumorigenesis. Peptides. 1999; 20: 1247-1262.
Emons G, and Schally AV. The use of luteinizing releasing hormone agonists and antagonist in gynecological cancers. Hum. Reprod. Update. 1994; 9: 1364-1379.
How to Cite
Downloads
Downloads
Published
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
